159 related articles for article (PubMed ID: 16043162)
21. hERG 1b is critical for human cardiac repolarization.
Jones DK; Liu F; Vaidyanathan R; Eckhardt LL; Trudeau MC; Robertson GA
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):18073-7. PubMed ID: 25453103
[TBL] [Abstract][Full Text] [Related]
22. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
23. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
24. In silico study of action potential and QT interval shortening due to loss of inactivation of the cardiac rapid delayed rectifier potassium current.
Zhang H; Hancox JC
Biochem Biophys Res Commun; 2004 Sep; 322(2):693-9. PubMed ID: 15325285
[TBL] [Abstract][Full Text] [Related]
25. Spatial gradients in action potential duration created by regional magnetofection of hERG are a substrate for wavebreak and turbulent propagation in cardiomyocyte monolayers.
Campbell K; Calvo CJ; Mironov S; Herron T; Berenfeld O; Jalife J
J Physiol; 2012 Dec; 590(24):6363-79. PubMed ID: 23090949
[TBL] [Abstract][Full Text] [Related]
26. The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia.
Scherer CR; Lerche C; Decher N; Dennis AT; Maier P; Ficker E; Busch AE; Wollnik B; Steinmeyer K
Br J Pharmacol; 2002 Nov; 137(6):892-900. PubMed ID: 12411421
[TBL] [Abstract][Full Text] [Related]
27. Effect of S5P alpha-helix charge mutants on inactivation of hERG K+ channels.
Clarke CE; Hill AP; Zhao J; Kondo M; Subbiah RN; Campbell TJ; Vandenberg JI
J Physiol; 2006 Jun; 573(Pt 2):291-304. PubMed ID: 16556651
[TBL] [Abstract][Full Text] [Related]
28. High affinity open channel block by dofetilide of HERG expressed in a human cell line.
Snyders DJ; Chaudhary A
Mol Pharmacol; 1996 Jun; 49(6):949-55. PubMed ID: 8649354
[TBL] [Abstract][Full Text] [Related]
29. Not all hERG pore domain mutations have a severe phenotype: G584S has an inactivation gating defect with mild phenotype compared to G572S, which has a dominant negative trafficking defect and a severe phenotype.
Zhao JT; Hill AP; Varghese A; Cooper AA; Swan H; Laitinen-Forsblom PJ; Rees MI; Skinner JR; Campbell TJ; Vandenberg JI
J Cardiovasc Electrophysiol; 2009 Aug; 20(8):923-30. PubMed ID: 19490267
[TBL] [Abstract][Full Text] [Related]
30. Time course and voltage dependence of expressed HERG current compared with native "rapid" delayed rectifier K current during the cardiac ventricular action potential.
Hancox JC; Levi AJ; Witchel HJ
Pflugers Arch; 1998 Nov; 436(6):843-53. PubMed ID: 9799397
[TBL] [Abstract][Full Text] [Related]
31. Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome.
Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
Physiol Rep; 2018 Sep; 6(17):e13845. PubMed ID: 30175559
[TBL] [Abstract][Full Text] [Related]
32. The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C.
McPate MJ; Duncan RS; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2005 Aug; 334(2):441-9. PubMed ID: 16011830
[TBL] [Abstract][Full Text] [Related]
33. Deciphering hERG channels: molecular basis of the rapid component of the delayed rectifier potassium current.
Jonsson MK; van der Heyden MA; van Veen TA
J Mol Cell Cardiol; 2012 Sep; 53(3):369-74. PubMed ID: 22742967
[TBL] [Abstract][Full Text] [Related]
34. Novel Brugada syndrome-causing mutation in ion-conducting pore of cardiac Na+ channel does not affect ion selectivity properties.
Amin AS; Verkerk AO; Bhuiyan ZA; Wilde AA; Tan HL
Acta Physiol Scand; 2005 Dec; 185(4):291-301. PubMed ID: 16266370
[TBL] [Abstract][Full Text] [Related]
35. Identification through action potential clamp of proarrhythmic consequences of the short QT syndrome T618I hERG 'hotspot' mutation.
Du C; Zhang H; Harmer SC; Hancox JC
Biochem Biophys Res Commun; 2022 Mar; 596():49-55. PubMed ID: 35114584
[TBL] [Abstract][Full Text] [Related]
36. Quantitative prediction of the arrhythmogenic effects of de novo hERG mutations in computational models of human ventricular tissues.
Benson AP; Al-Owais M; Holden AV
Eur Biophys J; 2011 May; 40(5):627-39. PubMed ID: 21234558
[TBL] [Abstract][Full Text] [Related]
37. Cardiac channelopathies associated with infantile fatal ventricular arrhythmias: from the cradle to the bench.
Kato K; Makiyama T; Wu J; Ding WG; Kimura H; Naiki N; Ohno S; Itoh H; Nakanishi T; Matsuura H; Horie M
J Cardiovasc Electrophysiol; 2014 Jan; 25(1):66-73. PubMed ID: 24112685
[TBL] [Abstract][Full Text] [Related]
38. Direct block of hERG potassium channels by the protein kinase C inhibitor bisindolylmaleimide I (GF109203X).
Thomas D; Hammerling BC; Wimmer AB; Wu K; Ficker E; Kuryshev YA; Scherer D; Kiehn J; Katus HA; Schoels W; Karle CA
Cardiovasc Res; 2004 Dec; 64(3):467-76. PubMed ID: 15537500
[TBL] [Abstract][Full Text] [Related]
39. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
Park SJ; Kim KS; Kim EJ
J Appl Toxicol; 2008 Mar; 28(2):104-11. PubMed ID: 17516459
[TBL] [Abstract][Full Text] [Related]
40. In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Romero L; Trenor B; Yang PC; Saiz J; Clancy CE
J Mol Cell Cardiol; 2015 Oct; 87():271-82. PubMed ID: 26859003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
